The Supreme Court Just Ruled on Roundup Claims — Here Is What It Means for You
You heard the news. The Supreme Court ruled that federal pesticide law blocks some state-law claims against Monsanto and Bayer over Roundup weedkiller. If you or someone you love used Roundup and later developed cancer — especially Non-Hodgkin lymphoma — you may be wondering whether the door to compensation just closed. It did not close all the way. But it narrowed, and understanding exactly which doors remain open is now the most important thing standing between your family and a recovery.
We are Attorney911 — The Manginello Law Firm. We are writing to you as the trial team that handles toxic-tort and mass-tort cases, and we are going to tell you exactly what this ruling held, what it did NOT hold, which legal theories are still alive, and what you need to do right now to protect your claim. This page is legal information, not legal advice — but it is the information we wish every person diagnosed with cancer after years of Roundup exposure had before they talked to anyone, including us.
The ruling was 7-2. Justice Kavanaugh wrote the majority opinion. The Court held that the Federal Insecticide, Fungicide, and Rodenticide Act — the federal pesticide law known as FIFRA — preempts state-law failure-to-warn claims that would require cancer warnings on Roundup labels beyond what the Environmental Protection Agency has approved. Because the EPA approved Roundup’s label without requiring a cancer warning, and because federal law requires Monsanto to sell Roundup with that EPA-approved label, the Court said Missouri tort law cannot impose a “different” labeling requirement — which is what a jury verdict finding inadequate warnings effectively does.
Justice Jackson dissented, joined by Justice Gorsuch. She argued the majority misinterpreted FIFRA’s preemption scope and left the plaintiff — a cancer patient who had won a $1.25 million jury verdict — without a remedy.
Here is the single most important thing you need to understand: the Supreme Court did not rule that Roundup does not cause cancer. It did not rule that Monsanto did nothing wrong. It did not dismiss every Roundup lawsuit. It ruled on one specific legal theory — failure to warn through labeling — and held that federal law occupies that particular field for FIFRA-regulated pesticides. Other legal theories remain. A $7.25 billion class settlement remains open. And the science connecting glyphosate to cancer is still being fought over in courtrooms across the country.
Let us walk you through every piece of it.
What the Supreme Court Actually Held — and What It Did Not
The ruling came from a Missouri case. A man named John Durnell — a cancer patient — sued Monsanto, which is owned by Bayer, alleging that Roundup caused his cancer and that Monsanto failed to warn about the risk. A Missouri jury agreed and awarded him $1.25 million in compensatory damages. Monsanto appealed, arguing that FIFRA’s express preemption clause bars state-law claims that would require pesticide labels to carry warnings the EPA did not approve.
The Supreme Court agreed with Monsanto — but only on the failure-to-warn theory.
FIFRA’s express preemption clause prohibits states from imposing labeling or packaging requirements “different from” those required under federal law.
That is the language the majority relied on. The EPA approved Roundup’s label. The approved label does not include a cancer warning — the EPA currently classifies glyphosate as “unlikely to be a human carcinogen.” Federal law requires Monsanto to sell Roundup with that EPA-approved label. So when a state tort jury says the label should have carried a cancer warning, it is effectively imposing a labeling requirement “different from” what federal law requires — and FIFRA says states cannot do that.
What the ruling DID:
– It held that FIFRA preempts state-law failure-to-warn claims that seek to impose cancer-warning requirements on pesticide labels beyond what the EPA has approved
– It puts the $1.25 million Durnell verdict at risk of reversal or remand
– It narrows the primary theory that drove many prior Roundup verdicts
– It constrains the failure-to-warn pathway nationwide for FIFRA-regulated pesticides
What the ruling did NOT do:
– It did not rule on whether Roundup causes cancer — the ruling was purely about FIFRA’s preemption of state labeling requirements, not about scientific causation
– It did not eliminate all Roundup lawsuits — alternative legal theories remain potentially viable
– It did not affect the $7.25 billion class settlement, which operates as a contractual recovery framework alongside the regulatory system
– It did not change the scientific dispute between the EPA and the International Agency for Research on Cancer, which classified glyphosate as a “probable human carcinogen” (Group 2A) in 2015
That scientific dispute is central. The EPA says glyphosate is unlikely to cause cancer in humans. IARC — the World Health Organization’s cancer research arm — says it probably does. Both cannot be right. And that disagreement creates a genuine factual dispute that juries are entitled to weigh, even after the preemption ruling. What the Supreme Court removed was one pathway to put that dispute in front of a jury. It did not remove all of them.
Which Roundup Claims Are Affected — and Which Legal Theories Survive
This is the section that matters most to you. If you have a Roundup case — or think you might — you need to know which theories the ruling killed and which are still breathing.
Failure to warn — now substantially foreclosed. The theory that Monsanto failed to adequately warn users of Roundup’s cancer risk was the engine of the early Roundup litigation. It produced verdicts. It produced settlements. The Supreme Court has now held that for FIFRA-regulated pesticides where the EPA-approved label omits the warning at issue, this theory is preempted. If your case rests entirely on “they should have put a cancer warning on the label,” the ruling is a serious — potentially fatal — obstacle. This is the honest truth, and we will not soften it.
Design defect — potentially viable. This theory says Roundup is unreasonably dangerous by design, regardless of what the label says. The question is not “should the label have warned you?” but “should this product have been designed or formulated this way at all?” This theory is not premised on imposing labeling requirements different from EPA-approved labels — it attacks the product itself. FIFRA’s preemption clause is labeling-specific. While defendants will argue that any design-defect claim implicitly demands a label change, the theory is structurally distinct from failure-to-warn and remains a potential avenue for plaintiffs who can prove the product is inherently dangerous.
Negligent testing and research — potentially viable. This theory says Monsanto failed to conduct adequate safety testing or concealed unfavorable research about glyphosate’s carcinogenic potential. The claim is about what the company did or did not do in its laboratories and research programs — not about what the label says. If it is not premised on imposing labeling requirements different from EPA-approved labels, it may survive preemption. Internal corporate documents showing what Monsanto knew about cancer risk, and when, are the fuel for this theory.
Fraudulent misrepresentation and marketing — potentially viable. This theory targets representations to consumers, regulators, or the scientific community that extend beyond the label content. If Monsanto made public statements, marketing claims, or regulatory submissions that misrepresented the safety profile of glyphosate — and if internal documents show knowledge of and concealment of cancer risk — this theory operates outside the labeling channel that FIFRA preempts. Prior Roundup litigation produced internal Monsanto documents that may be accessible through discovery coordination, and those documents are the backbone of this claim.
The bottom line: the ruling narrowed the litigation, it did not end it. But the cases that survive will be built differently than the ones that came before. They will be built on corporate conduct, not label content — and that means the internal documents are now more valuable than ever.
The Monsanto and Bayer Defendant Structure — Who You Are Actually Fighting
When you sue over Roundup, you are suing a corporate family with enormous resources and a deliberate structure. Understanding that structure is part of understanding where the money is and who is responsible.
Monsanto Company is the manufacturer of Roundup herbicide. Monsanto designed, tested, registered, marketed, and sold the product. Monsanto is the entity that conducted the research, submitted the FIFRA registrations to the EPA, and made the public statements about glyphosate’s safety. In the litigation, Monsanto is the primary defendant — the company whose conduct is at issue.
Bayer AG is the German pharmaceutical and life sciences conglomerate that acquired Monsanto in 2018 for approximately $63 billion. When Bayer bought Monsanto, it assumed Monsanto’s litigation exposure — all of it, including the tens of thousands of Roundup cancer claims that were already pending and the ones that would follow. Bayer is the deep-pocket parent entity backing all Roundup litigation and the $7.25 billion class settlement. Bayer’s acquisition of Monsanto was, in hindsight, one of the most litigation-burdened corporate acquisitions in history — and Bayer has been working to resolve the exposure ever since.
The corporate-structure reality matters because Bayer has the resources to pay any successful claim or settlement-approved award. Collectibility is not the issue in Roundup cases — the issue is proving your claim under the surviving legal theories and navigating the settlement framework before deadlines close.
Bayer has also been pursuing what amounts to a legislative strategy — seeking a federal legislative solution that would shield it from state failure-to-warn claims, which is part of the context for why the Supreme Court case reached the Court when it did. The preemption ruling accomplishes through the judiciary what Bayer was also seeking through Congress. Understanding this backdrop helps you understand that the company has been fighting on multiple fronts — and the fight is not over.
The $7.25 Billion Class Settlement — What It Covers and How It Works
Even as the Supreme Court was considering the preemption question, a separate $7.25 billion class settlement was being structured to cover current and future Roundup exposure claims. This settlement operates alongside — not within — the FIFRA regulatory framework. It is a contractual recovery pathway, meaning it exists because Bayer agreed to it, not because a federal statute created it.
Current status: The settlement remains pending final approval. It covers both current claimants (people who have already filed suit or registered claims) and future claimants (people who may develop cancer after the settlement date). This dual structure is critical because it means that if you have not yet filed a claim but were exposed to Roundup and later developed cancer, you may still be able to participate.
What individual compensation depends on:
– Injury severity — ranging from initial diagnosis to terminal illness, with tier classifications that determine the compensation level
– Exposure duration and intensity — how long you used Roundup, how frequently, and in what quantities
– Medical documentation — pathology reports, treatment records, and medical certifications that establish your diagnosis and its severity
– Claim timing — settlement class deadlines are administratively enforced, and missing them may foreclose recovery through this pathway
What you need to understand about the relationship between the ruling and the settlement: The Supreme Court’s preemption ruling does not affect the settlement. The settlement is a contract. Bayer agreed to pay into the fund regardless of how the preemption question was resolved. The ruling may actually increase the settlement’s importance — because the failure-to-warn pathway is now narrowed, the settlement framework becomes the primary recovery route for many claimants who would have previously pursued individual litigation.
But here is the catch: you need to evaluate whether your individual case is better served by participating in the settlement or by pursuing standalone litigation on the non-preempted theories — design defect, negligent testing, fraudulent marketing. That evaluation depends on your specific exposure history, your cancer type and severity, the strength of your specific causation evidence, and the deadlines that apply to your situation. A farmer who sprayed Roundup for twenty years and has a confirmed Non-Hodgkin lymphoma diagnosis may have a very different calculation than a homeowner who used Roundup occasionally on a garden bed.
The Medicine — Non-Hodgkin Lymphoma and Glyphosate Exposure
If you are reading this page, there is a significant chance that you or someone you love has been diagnosed with Non-Hodgkin lymphoma — the cancer type most frequently associated with Roundup litigation. You deserve to understand what this disease is and why the connection to glyphosate is scientifically contested.
Non-Hodgkin lymphoma (NHL) is a cancer that begins in the lymphatic system — the body’s disease-fighting network. It develops when white blood cells called lymphocytes develop mutations that cause them to grow uncontrollably. There are many subtypes of NHL, and the specific subtype matters for both treatment and for the causation analysis in a legal case.
The mechanism at issue: Glyphosate is a broad-spectrum herbicide — the active ingredient in Roundup. The question is whether glyphosate exposure can cause the kind of cellular damage that leads to NHL. IARC’s 2015 classification as a “probable human carcinogen” (Group 2A) was based on “limited” evidence of cancer in humans and “sufficient” evidence in experimental animals. The EPA’s contrary position — that glyphosate is “unlikely to be a human carcinogen” — is based on a different evaluation of the same body of evidence, with different weight given to different studies.
What this means for your case: The EPA-IARC disagreement is not a problem for your case — it is the case. A genuine dispute among qualified scientific bodies about whether a chemical causes cancer is exactly the kind of factual question that juries are supposed to resolve. Your experts in toxicology, epidemiology, and oncology bridge the gap between general causation (glyphosate can cause cancer) and specific causation (your cancer was caused by Roundup exposure). That bridge is built from your exposure history, your medical records, and the scientific literature.
What the family observes over time: Cancer treatment is grueling. Chemotherapy, immunotherapy, radiation, stem-cell transplants — each carries its own burden. The person you knew before the diagnosis changes: the fatigue, the fear, the appointments that take over the calendar, the financial pressure of medical bills that arrive while paychecks stop. If the cancer is terminal, the trajectory is one of decline, remission, and recurrence — a cycle that can last years. These are not abstract damages. They are the daily reality your case is trying to compensate.
The proof problem the defense exploits: Non-Hodgkin lymphoma has many possible causes — genetic factors, viral infections, immunosuppression, other chemical exposures. The defense will argue your cancer came from somewhere other than Roundup. The counter is your exposure history: the duration, frequency, and intensity of your glyphosate use, documented as specifically as possible, combined with expert testimony that ties your exposure to your disease. This is why exposure documentation is the single most important evidence in a Roundup case — not the label, not the corporate documents, but your own history of contact with this chemical.
The Science War — EPA vs. IARC, and Why It Matters to You
The central scientific fact in every Roundup case is this: two qualified scientific bodies have looked at the same chemical and reached opposite conclusions about whether it causes cancer. This is not a footnote — it is the case.
The Environmental Protection Agency classifies glyphosate as “unlikely to be a human carcinogen.” This classification is part of the federal regulatory framework under FIFRA — it is the basis on which the EPA approved Roundup’s label without a cancer warning. The EPA’s position carries the weight of the federal regulatory system behind it.
The International Agency for Research on Cancer — IARC, the specialized cancer agency of the World Health Organization — classified glyphosate as a “probable human carcinogen” (Group 2A) in 2015. IARC’s Group 2A classification means there is limited evidence of carcinogenicity in humans and sufficient evidence in experimental animals. IARC is one of the most respected cancer-research bodies in the world. Its classifications are used globally to guide cancer-prevention policy.
These two positions are irreconcilable. One of them is wrong. And the fact that they disagree is exactly what makes the causation question a genuine factual dispute for a jury — not a settled scientific fact that can be taken away from the courtroom.
The Supreme Court’s ruling did not resolve this dispute. It did not say the EPA is right and IARC is wrong. It said that under FIFRA, the EPA’s labeling decision controls what the label must say — and state tort law cannot add warnings the EPA did not require. The science was not the question before the Court. The science remains the question before the jury, on the theories that survive.
For your case, this means your experts need to address both classifications. They need to explain why the IARC classification is the more reliable one for your specific circumstances — and they need to do it in a way that acknowledges the EPA position without being undermined by it. This is not impossible. It is what toxic-tort experts do. But it requires expertise, preparation, and an expert who can withstand cross-examination from a defense team that has been fighting this battle for years.
The Evidence Clock — What Exists, Who Holds It, and How Fast It Disappears
Every mass-tort case is a race against evidence destruction. In Roundup cases, that race is even more urgent because the Supreme Court ruling has shifted which evidence matters most. Here is what exists, who holds it, and how fast it can legally die.
Medical records documenting your cancer diagnosis. Pathology reports, treatment history, and prognosis establish the severity of your injury, the type of cancer (typically Non-Hodgkin lymphoma), the temporal relationship to your exposure, and the baseline for damages. These are held by hospitals, oncology practices, and pathology labs. Compile them immediately. Pathology blocks and tissue samples should be preserved for potential biomarker analysis — this is not standard practice, so you may need to specifically request it.
Exposure history documentation. Work records, Roundup purchase receipts, usage logs, and witness statements establish specific causation by quantifying the duration, frequency, and intensity of your glyphosate exposure. This is the most critical evidence category in a Roundup case — and it is the fastest-dying. Memories fade. Receipts are discarded. Employment records become harder to obtain over time. Co-workers who can corroborate your exposure move, retire, or pass away. If you were a farmer, your spray records, equipment logs, and pesticide-application permits may exist in county or state agricultural offices. If you were a commercial applicator, your employer’s records of what you sprayed, when, and in what quantities are the backbone of exposure proof. If you were a homeowner, receipts from garden-supply stores, credit-card records, and the testimony of family members who watched you use Roundup are what you have — and those receipts are being thrown away every day.
Internal Monsanto and Bayer corporate documents. Research data, safety studies, internal communications about glyphosate carcinogenicity, and documents related to IARC’s 2015 classification are the fuel for the surviving non-preempted theories — design defect, negligent testing, fraudulent marketing. Prior Roundup litigation produced internal documents that may be accessible through discovery coordination. These are subject to corporate document-retention policies and protective orders. The documents that emerged in earlier cases — internal emails, research memos, ghostwriting of scientific literature — are now more valuable because the theories they support are the ones that survived the Supreme Court ruling.
EPA registration files and FIFRA compliance records. These establish the regulatory history of Roundup’s label approvals and any communications between Monsanto and the EPA regarding cancer concerns. Government records are relatively stable, but Freedom of Information Act requests require significant lead time — months, not weeks.
Settlement class registration documentation. Medical certifications, exposure attestations, and claim forms are required for participation in the $7.25 billion class settlement framework. These deadlines are administratively enforced. Missing them may foreclose recovery through that pathway entirely. This is not a soft deadline — it is a hard, administrative cutoff.
Expert witness analyses. Toxicologists, epidemiologists, occupational-medicine specialists, and oncologists bridge the gap between general causation and specific causation. Their expert reports must reflect current scientific consensus and address the EPA-IARC disagreement head-on. The scientific literature evolves — what was publishable five years ago may have been superseded. Your experts need to be current, and their work product needs to be developed before the science shifts under them.
The preservation principle is simple: the day you call a lawyer is the day the clock starts working for you instead of against you. Every day before that call, evidence is dying — legally, routinely, and without anyone noticing.
What Your Case May Be Worth — Honest Numbers, Not Promises
We are not going to tell you your case is worth millions without knowing your facts. What we will tell you is the current picture — and it is shaped by two forces working in different directions.
The Supreme Court’s preemption ruling has reduced the ceiling for standalone failure-to-warn verdicts. The $1.25 million Durnell verdict — the one the Supreme Court just put at risk — represents the kind of compensatory award that failure-to-warn claims produced. With that theory substantially foreclosed, the individual-litigation ceiling is lower for most claimants. But design defect and non-labeling negligence theories may preserve higher-value litigation paths for plaintiffs with compelling exposure histories and strong specific-causation evidence.
The $7.25 billion class settlement provides a predictable but potentially lower individual recovery floor. Individual compensation amounts under the settlement depend on injury tier classification, exposure duration, medical documentation, and claim timing. The settlement is designed to pay across a large population of claimants — which means individual amounts, while real, may be smaller than what a strong individual verdict could produce.
The general range we see in the current picture:
– Lower end (initial diagnosis, shorter exposure, settlement participation): approximately $50,000 and up
– Higher end (severe injury, long-term heavy exposure, strong causation, non-preempted theories): potentially up to $2,000,000 or more
These are not predictions. They are the range the current legal reality produces, and they depend entirely on your specific facts. Past results depend on the facts of each case and do not guarantee future outcomes.
What the ruling has done is compress the range — the ceiling is lower, the floor is the settlement, and the middle is where the non-preempted theories live. A claimant with twenty years of heavy occupational exposure, a confirmed NHL diagnosis, and internal corporate documents showing Monsanto knew about cancer risk is in a very different position than a claimant with occasional homeowner use and a recent diagnosis. The evaluation has to be individual.
The Defense Playbook — What Monsanto and Bayer Will Do, and How to Counter It
Now that the Supreme Court has given Monsanto and Bayer the preemption ruling they sought, their defense strategy will shift. Here are the plays you can expect — and the counter to each.
Play 1: “The Supreme Court killed all Roundup cases.” This is already the narrative the defense is pushing. It is false. The ruling preempted one theory — failure to warn through labeling. Design defect, negligent testing, and fraudulent marketing theories are not premised on labeling requirements and remain potentially viable. The counter is to build your case on the surviving theories, not to concede the field.
Play 2: Pressure quick, low settlement using the ruling as leverage. Adjusters and defense counsel will cite the Supreme Court ruling to push claimants into accepting lower settlement amounts than they might otherwise receive. The argument is: “your failure-to-warn claim is dead, take what we are offering.” The counter is to evaluate whether your case has non-preempted-theory value that exceeds the settlement offer — and to remember that the $7.25 billion class settlement provides a floor that does not depend on the preemption ruling at all.
Play 3: Attack causation using the EPA classification. The defense will lean heavily on the EPA’s position that glyphosate is “unlikely to be a human carcinogen” to argue that your cancer was not caused by Roundup. The counter is the IARC classification — Group 2A, “probable human carcinogen” — and the genuine scientific dispute between two qualified bodies. A jury is entitled to weigh both positions. Your experts in toxicology and oncology are the bridge between the competing classifications and your specific case.
Play 4: Argue alternative causation. The defense will point to other possible causes of Non-Hodgkin lymphoma — genetic factors, viral infections, other chemical exposures, immunosuppression. The counter is your exposure history: the more specifically and comprehensively you can document your glyphosate exposure — duration, frequency, intensity — the harder it is for the defense to attribute your cancer to something else.
Play 5: Run out the clock on the statute of limitations. The defense will bet that if they delay long enough, your claim will expire. Every state has a deadline for filing a personal-injury lawsuit — the personal-injury statute of limitations. In toxic-tort cases, many states apply a “discovery rule” — the clock starts when you discovered, or should have discovered, that your injury was connected to the exposure, not when the exposure itself occurred. But some states have outer deadlines (statutes of repose) that can cut off a claim even before discovery. The counter is to act now, not after the legal reality shifts further. The SOL varies by state — confirm the deadline that applies to you with a lawyer in your jurisdiction immediately.
The Roundup MDL and the National Litigation Picture
Thousands of Roundup cases are consolidated in a federal multidistrict litigation — MDL No. 2741, In re: Roundup Products Liability Litigation, before Judge Vince Chhabria in the Northern District of California. As of mid-2026, thousands of actions remain pending in this MDL.
The MDL is not a class action. Each plaintiff keeps an individual case. The MDL centralizes pretrial proceedings — discovery, motion practice, expert challenges — so that the shared factual and legal questions are handled once rather than in thousands of separate courts. After pretrial proceedings, individual cases may be remanded to their original districts for trial, or they may be resolved through settlement or bellwether trials.
The Supreme Court’s preemption ruling affects every case in the MDL that rests on failure-to-warn — and the MDL judge will now have to grapple with how to manage the remaining cases under the new legal reality. Cases built on non-preempted theories will continue. Cases built solely on failure-to-warn face serious headwinds.
If your case is in the MDL, or if you are considering filing, you need to understand that the MDL is not a passive waiting room. Deadlines apply. Discovery obligations apply. Expert disclosures apply. And the settlement framework has its own parallel timeline. Sitting still is not a strategy — it is a way to lose your claim through inattention.
What to Do in the First 72 Hours — Your Practical Roadmap
If you have been diagnosed with cancer after Roundup exposure, or if a family member has, here is what you should do — starting today, not next week.
Day 1: Gather your medical records. Request your complete medical file — pathology reports, treatment records, diagnostic imaging, physician notes. If you have pathology tissue blocks, ask that they be preserved. These are the foundation of your injury proof, and they are the one category of evidence that is relatively stable — but only if you request it.
Day 1: Write down your exposure history. Do this while your memory is fresh — or as fresh as it will ever be. Every job where you used Roundup. Every season you sprayed. How often. How much. What equipment you used. Who you worked with. What the weather was like on spray days. Whether you wore protective equipment. Whether you were ever drenched, splashed, or exposed to drift. This is the single most important document in your case, and nobody else can write it for you. If you are a farmer, pull your spray records and pesticide-application permits. If you were a commercial applicator, pull your employment records. If you were a homeowner, pull your credit-card statements and receipts from garden-supply purchases.
Day 2: Do not sign anything from Monsanto, Bayer, or any claims administrator without having a lawyer review it. This includes settlement offers, release forms, class-action notices, and anything that asks you to waive your rights. The Supreme Court ruling has created a moment where the defense has leverage — and that is exactly when quick, low offers arrive. A release you sign today may extinguish claims that could be worth far more under non-preempted theories.
Day 2: Do not give a recorded statement. If an insurance adjuster, claims administrator, or investigator calls and asks you to “just tell us what happened” on a recording, decline. Recorded statements are engineered to be quoted against you — to create a “symptom gap” or a timeline inconsistency that the defense can exploit later. Everything you say can and will be used to minimize your claim. Talk to a lawyer first.
Day 3: Check the settlement class deadline. The $7.25 billion class settlement has administratively enforced deadlines. If you are eligible — current or future claimant with Roundup exposure and a cancer diagnosis — you need to know when the registration window closes. Missing this deadline may foreclose recovery through the settlement pathway entirely.
Day 3: Do not post about your case on social media. Defense investigators monitor social media. A photo of you at a family barbecue can be used to argue your pain and suffering is exaggerated. A post about your diagnosis timeline can be twisted to undermine your causation evidence. Set your accounts to private and stop posting about your health, your work history, or your legal situation.
Ongoing: Call us. The consultation is free. The call is confidential. We will tell you whether you have a case worth pursuing, which theory or theories apply to your facts, whether you are better served by the settlement or by individual litigation, and what the deadline is in your state. If we are not the right fit for your case, we will tell you that too.
Frequently Asked Questions
Can I still file a Roundup lawsuit after the Supreme Court ruling?
Yes — but the path is different. The ruling preempts failure-to-warn claims that seek to impose cancer-warning requirements on Roundup labels beyond what the EPA approved. It does not eliminate all claims. Design defect, negligent testing, and fraudulent marketing theories remain potentially viable. And the $7.25 billion class settlement remains open to qualified claimants. If you have a Roundup exposure history and a cancer diagnosis, you should have your case evaluated under the surviving theories as soon as possible.
Will my existing Roundup case be dismissed?
Not automatically. If your case is built solely on failure-to-warn, it faces a serious preemption challenge. But if your case includes design defect, negligent testing, or fraudulent marketing claims — or if you are participating in the settlement framework — those components are not preempted by the ruling. Your attorney should evaluate your case’s theory mix and adjust strategy accordingly. Some cases will need to be repleaded to emphasize the surviving theories. Others may need to shift toward the settlement pathway.
How does the $7.25 billion settlement work?
The settlement is a contractual agreement between Bayer and a class of current and future Roundup claimants. It establishes a fund that pays compensation based on injury tier, exposure duration, medical documentation, and claim timing. It operates alongside the FIFRA regulatory framework — the Supreme Court’s preemption ruling does not affect it. To participate, you must register, provide medical certifications and exposure attestations, and meet administratively enforced deadlines. Missing those deadlines may foreclose recovery through the settlement pathway. The settlement provides a predictable recovery floor, but individual amounts may be lower than what a strong individual verdict could produce under non-preempted theories.
Did the Supreme Court rule that Roundup causes cancer?
No. The Supreme Court did not rule on whether Roundup causes cancer. The ruling was purely about FIFRA’s preemption of state-law labeling requirements — whether state tort law can impose cancer-warning requirements that differ from what the EPA approved. The scientific question of whether glyphosate causes Non-Hodgkin lymphoma was not before the Court and remains contested. The EPA says glyphosate is “unlikely to be a human carcinogen.” IARC says it is a “probable human carcinogen.” That dispute is alive and is the central battleground in the cases that survive.
How long do I have to file a Roundup claim?
The personal-injury statute of limitations varies by state — typically between two and six years, depending on the jurisdiction. Many states apply a “discovery rule” in toxic-tort cases, meaning the clock may start when you discovered, or reasonably should have discovered, that your cancer was connected to Roundup exposure — not when you were first exposed. Some states also have statutes of repose that impose an outer deadline regardless of discovery. The SOL in your state is a hard deadline — miss it and your claim is gone, no matter how strong it is. Confirm the deadline that applies to your situation with a lawyer immediately. Do not assume you have plenty of time, because the evidence is dying faster than the deadline is approaching.
What kind of cancer is associated with Roundup?
Non-Hodgkin lymphoma (NHL) is the cancer type most frequently associated with Roundup litigation. NHL is a cancer of the lymphatic system that begins in white blood cells called lymphocytes. The connection between glyphosate exposure and NHL is the subject of the EPA-IARC scientific dispute — IARC classified glyphosate as a “probable human carcinogen” in 2015, while the EPA maintains it is “unlikely to be a human carcinogen.” Other cancers have been studied in connection with glyphosate, but NHL has been the central focus of the Roundup litigation.
What evidence do I need for a Roundup case?
The most important evidence is your exposure history — documentation of how long, how often, and how intensively you used Roundup. This includes work records, purchase receipts, usage logs, spray records, and witness statements. Second is your medical evidence — pathology reports, treatment records, and diagnostic records that establish your cancer type and timeline. Third, in cases built on non-preempted theories, are internal corporate documents showing what Monsanto knew about cancer risk and when — these emerge through discovery and support design defect, negligent testing, and fraudulent marketing claims. Fourth is expert testimony from toxicologists, epidemiologists, and oncologists who can bridge general causation (glyphosate can cause cancer) and specific causation (your cancer was caused by your Roundup exposure).
Is it too late if I was exposed years ago?
Not necessarily. The discovery rule, which many states apply in toxic-tort cases, can mean the clock on your claim started when you learned — or should have learned — that your cancer was connected to Roundup, not when you were exposed decades ago. If you were just diagnosed, or if you only recently connected your diagnosis to your Roundup use, your claim may be timely even if your exposure was years or decades in the past. But this is not a guarantee — some states have outer deadlines that can cut off a claim regardless of discovery, and the SOL framework is state-specific. The only safe move is to have your deadline evaluated by a lawyer in your state now, not later.
Should I take the settlement or pursue individual litigation?
This depends entirely on your specific facts. The settlement provides a predictable recovery that does not depend on the preemption ruling — but individual amounts may be lower than what a strong individual case could produce under non-preempted theories. A claimant with heavy, long-term occupational exposure, a confirmed NHL diagnosis, and access to internal corporate documents may be better served by individual litigation on design defect or negligent testing theories. A claimant with lighter exposure or a weaker causation profile may be better served by the settlement’s guaranteed, if lower, recovery. This is an individualized evaluation that should be made with a lawyer who understands both the settlement framework and the surviving litigation theories.
What if my loved one died from cancer after using Roundup?
If your family member died from Non-Hodgkin lymphoma or another cancer associated with Roundup exposure, a wrongful-death claim may be available, depending on the state and the timing. Wrongful-death claims have their own statutes of limitations, beneficiary rules, and damage frameworks — all of which are state-specific. The Supreme Court’s preemption ruling affects wrongful-death claims built on failure-to-warn, but claims built on design defect, negligent testing, or fraudulent marketing theories may survive. If your loved one’s case was pending before the ruling, it may need to be evaluated under the new legal reality. Do not assume the ruling closed this door — talk to a lawyer who handles wrongful-death cases in the toxic-tort context.
Who We Are — and Why It Matters for Your Case
We are Attorney911 — The Manginello Law Firm, PLLC. We are a trial firm that handles toxic-tort and mass-tort cases, and we approach every case as the fight it actually is — not the fight the insurance company wants it to be.
Ralph Manginello is our managing partner. He has been licensed and practicing law for 27+ years — in courtrooms, including federal court. He was a journalist before he was a lawyer, which means he learned to find the story the evidence tells before he learned to argue it to a jury. He handles the cases other firms decline, and he approaches each one with a competitor’s hatred of losing. If you want to know more about who he is, you can read about Ralph Manginello here.
Lupe Peña is our associate attorney. He spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims from people exactly like you. He knows how the other side values claims, how they pick their medical experts, and how they engineer recorded statements to be used against you. Now he sits on your side of the table. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. If you want to know more about his background and the advantage it gives your case, read about Lupe Peña here.
We handle toxic-tort cases and wrongful-death claims — the exact practice areas this Supreme Court ruling affects. If you lost a family member to cancer after Roundup exposure, the wrongful-death path is one we know how to walk. If you are the one with the diagnosis, the toxic-tort path is where we start.
Our fee is contingency. We do not get paid unless we win your case. 33.33% before trial, 40% if the case goes to trial. The consultation is free. The call is confidential. And we have 24/7 live staff — not an answering service, but people who can take your call and start the process at any hour.
Past results depend on the facts of each case and do not guarantee future outcomes.
What the First Call Feels Like — and What It Costs
The first call costs nothing. It is free, it is confidential, and it is the moment the legal machinery starts working for you instead of against you.
When you call 1-888-ATTY-911, you will talk to a real person — not a robot, not a call center, not someone reading from a script. They will listen to what happened to you. They will ask about your Roundup use, your diagnosis, your treatment, and your timeline. They will not pressure you. They will not promise you a specific dollar amount. They will tell you whether we think you have a case, which legal theory or theories may apply, and what the next steps are.
If we take your case, the preservation letter goes out — the document that orders Monsanto, Bayer, and any other responsible party to freeze the evidence before it can be destroyed. Your medical records are compiled. Your exposure history is documented. Your case is evaluated against both the settlement framework and the individual-litigation path. And you are kept informed — because the worst feeling in a legal case is not knowing what is happening to your own claim.
If we are not the right fit for your case — if the settlement path is better for you than individual litigation, or if another firm is better positioned to handle your specific facts — we will tell you that. We are not interested in cases we cannot win. We are interested in making sure that every person who used Roundup and got cancer understands what the Supreme Court ruling did and did not do to their rights.
Hablamos Español. We serve your family fully in Spanish — consultations, case updates, and the entire legal process, in the language you are most comfortable in.
The Supreme Court narrowed the road. It did not close it. The question now is whether you walk down what remains of that road, or whether you let the ruling scare you away from a claim that may still have real value. That is a decision only you can make — but make it with the facts, not the fear.
Call us. 1-888-ATTY-911. Free consultation. No fee unless we win.